JP6640232B2 - クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンａ及びトキシンｂに対する四重特異性の八量体型結合剤及び抗体 - Google Patents

クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンａ及びトキシンｂに対する四重特異性の八量体型結合剤及び抗体 Download PDF

Info

Publication number
JP6640232B2
JP6640232B2 JP2017540865A JP2017540865A JP6640232B2 JP 6640232 B2 JP6640232 B2 JP 6640232B2 JP 2017540865 A JP2017540865 A JP 2017540865A JP 2017540865 A JP2017540865 A JP 2017540865A JP 6640232 B2 JP6640232 B2 JP 6640232B2
Authority
JP
Japan
Prior art keywords
peptide monomers
peptide
binder
monomers
toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017540865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018506972A5 (https=
JP2018506972A (ja
Inventor
ハンピン フェン
ハンピン フェン
ヨンジュン カン
ヨンジュン カン
ヨンロン チャン
ヨンロン チャン
ツィーヨン ヤン
ツィーヨン ヤン
リェンファ シー
リェンファ シー
Original Assignee
ユニバーシティ オブ メリーランド，ボルチモア
ユニバーシティ オブ メリーランド，ボルチモア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ メリーランド，ボルチモア, ユニバーシティ オブ メリーランド，ボルチモア filed Critical ユニバーシティ オブ メリーランド，ボルチモア
Publication of JP2018506972A publication Critical patent/JP2018506972A/ja
Publication of JP2018506972A5 publication Critical patent/JP2018506972A5/ja
Application granted granted Critical
Publication of JP6640232B2 publication Critical patent/JP6640232B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017540865A 2015-02-06 2016-02-05 クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンａ及びトキシンｂに対する四重特異性の八量体型結合剤及び抗体 Active JP6640232B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113046P 2015-02-06 2015-02-06
US62/113,046 2015-02-06
PCT/US2016/016852 WO2016127104A2 (en) 2015-02-06 2016-02-05 Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019233702A Division JP2020072685A (ja) 2015-02-06 2019-12-25 クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンａ及びトキシンｂに対する四重特異性の八量体型結合剤及び抗体

Publications (3)

Publication Number Publication Date
JP2018506972A JP2018506972A (ja) 2018-03-15
JP2018506972A5 JP2018506972A5 (https=) 2019-03-22
JP6640232B2 true JP6640232B2 (ja) 2020-02-05

Family

ID=56564887

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017540865A Active JP6640232B2 (ja) 2015-02-06 2016-02-05 クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンａ及びトキシンｂに対する四重特異性の八量体型結合剤及び抗体
JP2019233702A Withdrawn JP2020072685A (ja) 2015-02-06 2019-12-25 クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンａ及びトキシンｂに対する四重特異性の八量体型結合剤及び抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019233702A Withdrawn JP2020072685A (ja) 2015-02-06 2019-12-25 クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンａ及びトキシンｂに対する四重特異性の八量体型結合剤及び抗体

Country Status (6)

Country Link
US (1) US10961299B2 (https=)
EP (1) EP3253790A4 (https=)
JP (2) JP6640232B2 (https=)
AU (1) AU2016215087A1 (https=)
CA (1) CA2974720A1 (https=)
WO (1) WO2016127104A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7184336B2 (ja) 2015-10-13 2022-12-06 ザ ユニバーシティ オブ メリーランド，ボルチモア クロストリジウム・ディフィシル感染症に対する酵母ベースの免疫療法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US20200157224A1 (en) * 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
KR102763369B1 (ko) * 2017-06-25 2025-02-05 시스트이뮨, 인코포레이티드 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
AU2020287324A1 (en) * 2019-06-03 2022-01-20 Fzata, Inc. Humanized tetra-specific octavalent antibody against Clostridium difficile toxin A and B
CA3193741A1 (en) * 2020-09-02 2022-03-10 The Regents Of The University Of California A broadly neutralizing molecule against clostridium difficile toxin b

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006323412A1 (en) * 2005-12-06 2007-06-14 Domantis Limited Ligands that have binding specificity for EGFR and/or VEGF and methods of use therefor
US9023352B2 (en) * 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
US20160031971A9 (en) * 2007-02-20 2016-02-04 Tufts University Methods and compositions with a recombinant neutralizing binding protein for treating toxin exposure
KR20100052545A (ko) 2007-08-28 2010-05-19 바이오겐 아이덱 엠에이 인코포레이티드 Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물
NZ601117A (en) 2010-03-03 2014-06-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
US8702942B2 (en) 2010-12-17 2014-04-22 Malvern Instruments, Ltd. Laser doppler electrophoresis using a diffusion barrier
EP2961770A1 (en) 2013-02-26 2016-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
US11634502B2 (en) * 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
JP7184336B2 (ja) * 2015-10-13 2022-12-06 ザ ユニバーシティ オブ メリーランド，ボルチモア クロストリジウム・ディフィシル感染症に対する酵母ベースの免疫療法

Also Published As

Publication number Publication date
WO2016127104A2 (en) 2016-08-11
US10961299B2 (en) 2021-03-30
US20180244760A1 (en) 2018-08-30
EP3253790A4 (en) 2018-07-25
CA2974720A1 (en) 2016-08-11
JP2018506972A (ja) 2018-03-15
WO2016127104A3 (en) 2016-10-27
JP2020072685A (ja) 2020-05-14
AU2016215087A1 (en) 2017-08-17
EP3253790A2 (en) 2017-12-13

Similar Documents

Publication Publication Date Title
JP6640232B2 (ja) クロストリジウム・ディフィシル感染症の治療のための、クロストリジウム・ディフィシルのトキシンａ及びトキシンｂに対する四重特異性の八量体型結合剤及び抗体
US20230295340A1 (en) Muc1* antibodies
JP7378474B2 (ja) 抗－４－１ｂｂ抗体およびその用途
RU2687588C2 (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
JP2022528061A (ja) 抗クローディン１８．２抗体及びその用途
JP7184336B2 (ja) クロストリジウム・ディフィシル感染症に対する酵母ベースの免疫療法
US20190100597A1 (en) Cd20 binding molecules and uses thereof
CN109476734A (zh) Cd70和cd3的抗体构建体
KR20160074510A (ko) 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
JP2021526820A (ja) 癌治療のための抗ｏｘＭＩＦ／抗ＣＤ３抗体
CN101939337A (zh) 抗trka抗体及其衍生物
US20120269822A1 (en) Anti-Botulinum Neurotoxin a Single Domain Antibody Antibodies
JP2015531350A (ja) 末端修飾を有する抗原結合分子
CN118240082A (zh) Pd-1结合分子及其应用
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
WO2022184155A1 (zh) 抗ctla-4抗体及其应用
CN113444174B (zh) 金黄色葡萄球菌α-毒素特异性抗体及其应用
WO2022143550A1 (zh) 间皮素结合分子及其应用
CN113416249B (zh) 针对破伤风毒素的组合物
JP2022523009A (ja) 脱免疫化志賀毒素ａサブユニットエフェクターを含むｃｄ３８結合性タンパク質
US20240059764A1 (en) ANTIGEN-BINDING PROTEIN TARGETING STAPHYLOCOCCUS AUREUS a-HEMOLYSIS AND APPLICATION THEREOF
KR20220016152A (ko) 항-gal9 결합분자 활성화
CN107614524A (zh) 治疗
KR20240006506A (ko) 항-백시니아 바이러스 항원 항체 및 관련 조성물 및 방법
HK40122548A (zh) 抗cd44v6抗体及其用於治疗cd44v6过表达癌症的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171002

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20171002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191024

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191225

R150 Certificate of patent or registration of utility model

Ref document number: 6640232

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250